Prognosis of overall and disease-free survival in patients with grade 3 astrocytomas (anaplastic astrocytoma, WHO 2016)

Belyaev A.Yu.; Kobyakov G.L.; Shmakov P.N.; Efremov K.V.; Pronin I.N.; Usachev D.Yu.

doi:https://doi.org/10.17116/neiro20238704146

Close metadata

Abstract:

Anaplastic astrocytoma (AA) is a rare intracerebral tumor. Therefore, the number of studies devoted to risk factors of overall and disease-free survival is small. This single-center clinical study is devoted to various factors influencing prognosis of treatment in this group of patients.

MATERIAL AND METHODS

A retrospective study included 389 patients diagnosed with grade 3 astrocytoma. We analyzed dependence of overall and disease-free survival from the following factors: gender, age of onset of disease, tumor extent, surgery, neurological disorders before and after surgery (NANO grading system), Ki67 index, postoperative radio- and chemotherapy (number courses, treatment regimens).

RESULTS

Significant risk factors for overall and disease-free survival were spread and volume of tumor, postoperative neurological aggravation, Ki67 index, IDH mutation, radio- and chemotherapy. Age, frontal lobe tumor and disease manifestation variant were significant only for overall, but not for disease-free survival.

CONCLUSION

This study was based on material of one of the largest clinical series of patients with AA operated on in one center in «molecular» era. Our results are consistent with previous data. Analysis of tumor biology and risk factors for IDH-negative AA without molecular signs of glioblastoma may be perspective.

Keywords:

anaplastic astrocytoma

overall and disease-free survival

IDH mutation

radio- and chemotherapy

Authors:

Belyaev A.Yu.

Burdenko Neurosurgical Center

ORCID: 0000-0002-2337-6495

Kobyakov G.L.

Burdenko Neurosurgical Center

SPIN RSCI: 6138-9206
Scopus AuthorID: 56013296300
ORCID: 0000-0002-7651-4214

Shmakov P.N.

Burdenko Neurosurgical Center

ORCID: 0000-0001-8822-5826

Efremov K.V.

Burdenko Neurosurgical Center

ORCID: 0000-0002-4838-4723

Pronin I.N.

Burdenko Neurosurgical Center

SPIN RSCI: 9223-9217
Scopus AuthorID: 7006011755
ORCID: 0000-0002-4480-0275

Usachev D.Yu.

Burdenko Neurosurgical Center

ORCID: 0000-0002-8924-7346

Received:

14.01.2023

Accepted:

19.05.2023

Close metadata

References:

Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-Oncology. 2016;18(suppl 1):1-50. https://doi.org/10.1093/neuonc/nov297
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology. 2017;19(5):625-635. https://doi.org/10.1093/neuonc/nox029
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114(2):97-109. https://doi.org/10.1007/s00401-007-0243-4
Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, Wick W, Herold-Mende C, Aldape K, von Deimling A. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica. 2015;129(6):867-873. https://doi.org/10.1007/s00401-015-1438-8
Clinical recommendations: primary central nervous system tumors (In Russ.). https://cr.minzdrav.gov.ru/recomend/578
Christians A, Adel-Horowski A, Banan R, Lehmann U, Bartels S, Behling F, Barrantes-Freer A, Stadelmann C, Rohde V, Stockhammer F, Hartmann C. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathologica Communications. 2019;7(1):156. https://doi.org/10.1186/s40478-019-0817-0
Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Journal of Neuro-Oncology. 2016;129(3):505-514. https://doi.org/10.1007/s11060-016-2201-2
Feraco P, Bacci A, Ferrazza P, van den Hauwe L, Pertile R, Girlando S, Barbareschi M, Gagliardo C, Morganti AG, Petralia B. Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas. Diagnostics. 2020;10(4):247. https://doi.org/10.3390/diagnostics10040247
SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Science. 2012;103(2):269-273. https://doi.org/10.1111/j.1349-7006.2011.02134.x
McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463-469; discussion 469-470. https://doi.org/10.1227/01.NEU.0000349763.42238.E9
Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, Sayour E, Mitchell D, Quinones-Hinojosa A. The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. Journal of Neurosurgery. 2017;127(1):123-131. https://doi.org/10.3171/2016.7.JNS16396
Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncology. 2016;5(3):145-157. https://doi.org/10.2217/cns-2016-0002
Wahner HCW, Träger M, Bender K, Schweizer L, Onken J, Senger C, Ehret F, Budach V, Kaul D. Predicting survival in anaplastic astrocytoma patients in a single-center cohort of 108 patients. Radiation Oncology. 2020;15(1):282. https://doi.org/10.1186/s13014-020-01728-8
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine. 2009;360(8):765-773. https://doi.org/10.1056/NEJMoa0808710
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology. 2017;18(6):315-329. https://doi.org/10.1016/S1470-2045(17)30194-8
Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European Journal of Cancer. 2013;49(16):3477-3485. https://doi.org/10.1016/j.ejca.2013.06.039
Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology. 2018;20(1):103-112. https://doi.org/10.1093/neuonc/nox176
Carroll KT, Bryant AK, Hirshman B, Alattar AA, Joshi R, Gabel B, Carter BS, Harismendy O, Vaida F, Chen CC. Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection. World Neurosurgery. 2018;111:790-798. https://doi.org/10.1016/j.wneu.2017.12.165
Li HY, Sun CR, He M, Yin LC, Du HG, Zhang JM. Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes. World Neurosurgery. 2018;112:407-414. https://doi.org/10.1016/j.wneu.2018.01.055
Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC, Network P. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. The Oncologist. 2021;26(5):838-846. https://doi.org/10.1002/onco.13701
Preusser M, Hoeftberger R, Woehrer A, Gelpi E, Kouwenhoven M, Kros JM, Sanson M, Idbaih A, Brandes AA, Heinzl H, Gorlia T, Hainfellner JA, van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology. 2012;60(6):885-894. https://doi.org/10.1111/j.1365-2559.2011.04134.x
Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention. 2015;16(2):411-420. https://doi.org/10.7314/APJCP.2015.16.2.411
Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathology Oncology Research. 2006;12(3):143-147. https://doi.org/10.1007/BF02893360
Thotakura M, Tirumalasetti N, Krishna R. Role of Ki-67 labeling index as an adjunct to the histopathological diagnosis and grading of astrocytomas. Journal of Cancer Research and Therapeutics. 2014;10(3):641-645. https://doi.org/10.4103/0973-1482.139154
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology. 2013;31(3):337-343. https://doi.org/10.1200/JCO.2012.43.2674
van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology. 2013;31(3):344-350. https://doi.org/10.1200/JCO.2012.43.2229
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine. 2005;352(10):987-996. https://doi.org/10.1056/NEJMoa043330
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet. 2017;390(10103):1645-1653. https://doi.org/10.1016/S0140-6736(17)31442-3
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer. 2000;83(5):588-593. https://doi.org/10.1054/bjoc.2000.1316
Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. Journal of Clinical Oncology. 2001;19(2):509-518. https://doi.org/10.1200/JCO.2001.19.2.509
Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology. 2014;32(8):783-790. https://doi.org/10.1200/JCO.2013.49.3726
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology. 2017;18(6):315-329. https://doi.org/10.5167/uzh-141088
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. 2021;22(6):813-823. https://doi.org/10.1016/S1470-2045(21)00090-5
van den Bent MJ, Erridge S, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Wick W, Clement PM, Baurain J-F, Mason WP, Wheeler H, Weller M, Aldape KD, Wesseling P, Kros JM, Tesileanu M, Golfinopoulos V, Gorlia T, Baumer BG, French P. Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. Journal of Clinical Oncology. 2019;37(15 suppl):2000-2000. https://doi.org/10.1200/JCO.2019.37.15_suppl.2000
Bell EH, Won M, Fleming JL, Becker AP, McElroy JP, Shaw EG, Mehta MP, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson DB, Laack NN, Hunter GK, Crocker IR, Chakravarti A. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. Journal of Clinical Oncology. 2019;37(15 suppl):2002-2002. https://doi.org/10.1200/JCO.2019.37.15_suppl.2002
Brandes AA. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncology. 2006;8(3):253-260. https://doi.org/10.1215/15228517-2006-00